Lv1
12 积分 2026-04-08 加入
Abstract A124: CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior efficacy in preclinical models and improved safety in non-human primates
1天前
待确认
Structure-Based Discovery of Imidazo[4,5- c ]pyridine SARM1 Modulators Showing Paradoxical Activation
8天前
已完结
Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant
15天前
已完结
Discovery of GTA182, a Novel CNS-Active Tricyclic Amide MTA-Cooperative PRMT5 Inhibitor for MTAP -Deleted Cancers
1个月前
已完结
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D
1个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2个月前
已完结
Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity
3个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
6个月前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
6个月前
已完结